SuperworthOutlook Therapeutics EPS OTLK
Diluted earnings per share by quarter and over the last twelve months, from 2014.
- Last 12 months, to Jun 30, 2026
- −$0.86
- Latest quarter, Q3 FY26
- −$0.15
- Fiscal year 2025
- −$1.61
Outlook Therapeutics' earnings per share was −$0.86 over the twelve months to Jun 30, 2026.
In its latest quarter, Q3 FY26, it was −$0.15.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.61 | n/a |
| FY2024 | −$9.52 | n/a |
| FY2023 | −$4.73 | n/a |
| FY2022 | −$6.20 | n/a |
| FY2021 | −$7.20 | n/a |
| FY2020 | −$21.80 | n/a |
| FY2019 | −$50.80 | n/a |
| FY2018 | −$236.80 | n/a |
| FY2017 | −$276.80 | n/a |
| FY2016 | −$598.40 | n/a |
| FY2015 | −$862.40 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | −$0.15 | n/a | −$0.86 | |
| Q2 FY26 | −$0.05 | n/a | −$1.26 | |
| Q1 FY26 | −$0.38 | −153% | −$2.71 | |
| Q4 FY25 | −$0.28 | −217% | −$1.61 | |
| Q3 FY25 | −$0.55 | n/a | −$1.09 | |
| Q2 FY25 | −$1.50 | n/a | −$1.43 | |
| Q1 FY25 | $0.72 | n/a | −$7.94 | |
| Q4 FY24 | $0.24 | n/a | −$9.52 | |
| Q3 FY24 | −$0.89 | n/a | −$10.76 | |
| Q2 FY24 | −$8.01 | n/a | −$11.48 | |
| Q1 FY24 | −$0.86 | n/a | −$3.99 | |
| Q4 FY23 | −$1.00 | n/a | −$4.73 |
Against its peers
Companies in Healthcare nearest Outlook Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| OTLKOutlook Therapeutics | −$0.86 | |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| ICCCImmucell | $0.08 | −58% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| ELMDElectromed | $1.31 | +56% a year |
| UTMDUtah Medical Products | $3.28 | −12% a year |
| SPROSpero Therapeutics | $0.11 | |
| INFUInfuSystem | $0.41 | +78% a year |
| Peer median | $0.71 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Outlook Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.